There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.
A new analysis suggests that it may not be necessary to delay urate-lowering therapy in gout flares, and a study warns of the potential heightened risk for peripheral arterial disease in gout.